AUTOLOGOUS CELL PRODUCT REGULATION BY FDA SHOULD FOCUS ON MANUFACTURING PROCESSES, STANDARDIZED DATA COLLECTION; 10-YEAR FOLLOW-UP RECOMMENDED
This article was originally published in The Gray Sheet
Executive Summary
FDA does not plan to impose premarket requirements on autologous cell products used for structural repair, agency staffers indicated at a Nov. 16-17 workshop in Gaithersburg, Maryland. Instead, the agency likely will focus on industry recommendations to help ensure quality tissue manufacturing and uniform post-market testing standards.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.